Medicare covers 67 million Americans. Drug price negotiation — allowing the federal government to directly bargain with pharmaceutical companies for lower drug prices — has 89% public support. Yet Medicare’s private alternative, Medicare Advantage, faces growing scrutiny over denial rates and overpayments. The 2026 fight over healthcare will run through both.
- Medicare drug price negotiation polls at 89% support — among the highest individual policy approval ever measured in healthcare polling, crossing partisan lines at levels few other issues achieve.
- The IRA's first-ever Medicare negotiation authority covers 10 drugs (Eliquis, Jardiance, Xarelto, among others) with CBO-projected $98 billion in savings over 10 years.
- Medicare Advantage scrutiny: 30 million private-plan enrollees and rising denial rate concerns make Advantage changes electorally significant — any reform generates intense senior voter mobilization.
- Senior voters (65+) turn out at 70-75% in midterms — the highest of any cohort — making Medicare the single highest-leverage healthcare issue in any national election map.
Drug Price Negotiation: The Most Popular Policy in Healthcare
Allowing Medicare to negotiate directly with pharmaceutical companies for lower drug prices polls at 89% public support — making it among the most popular individual healthcare policies ever measured. The Inflation Reduction Act of 2022 included the first Medicare drug price negotiation authority in the program’s 57-year history, initially covering ten drugs including Eliquis, Jardiance, and Xarelto. The Congressional Budget Office projected $98 billion in savings over ten years.
In 2026, the negotiation program’s expansion and potential Republican efforts to roll it back are central Democratic talking points. KFF tracking polling shows 79% of Medicare beneficiaries say lowering their drug costs is their top healthcare priority. For senior voters, who cast ballots at 70%+ turnout rates in midterm elections, drug prices are not an abstract policy question — they are a monthly budget reality.
Medicare Advantage: The Private Sector Alternative Under Scrutiny
Medicare Advantage — the privatized alternative to traditional Medicare administered by insurance companies like UnitedHealth, CVS/Aetna, and Humana — now covers 33 million of Medicare’s 67 million beneficiaries, roughly half the program. Proponents argue it provides additional benefits (dental, vision, fitness memberships) and coordinates care more effectively. Critics, including the Government Accountability Office and the Senate Finance Committee, have raised concerns about prior authorization denials, marketing fraud, and tens of billions in improper overpayments to insurers.
A 2024 Senate Permanent Subcommittee on Investigations report found that Medicare Advantage insurers improperly denied hundreds of thousands of medically necessary claims and routinely delayed care through prior authorization requirements that far exceeded traditional Medicare’s processes. Sixty-one percent of Americans — and notably, 49% of Republicans — express concern about Medicare Advantage denial rates in recent polling. This is an emerging issue that did not register strongly in earlier polling cycles.
2026 Electoral Implications: Senior Voters and Swing Districts
In competitive House districts, the composition of voters who actually cast ballots in midterm elections is more weighted toward older voters than presidential year turnout data suggests. Voters 65 and older typically represent 25-30% of midterm electorate in swing districts — significantly above their share of the overall population. For these voters, Medicare is not a distant policy question. It is their primary healthcare as an issue.
Democrats are running Medicare protection ads in virtually every competitive Senate and House majority for 2026. The formula — pairing drug price negotiation as the positive message with attacks on Republicans’ budget proposals touching Medicare as the contrast — tests well with persuadable seniors, particularly in Florida, Pennsylvania, Michigan, and Arizona where older-skewing swing voters represent meaningful margins.
